Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States

作者：Datta Jashodeep; McMillan Matthew T; Ruffolo Luis; Lowenfeld Lea; Mamtani Ronac; Plastaras John P; Dempsey Daniel T; Karakousis Giorgos C; Drebin Jeffrey A; Fraker Douglas L; Roses Robert E^*

来源：Annals of Surgical Oncology, 2016, 23(9): 2936-2945.

DOI：10.1245/s10434-016-5224-1

National guidelines endorse adjuvant chemotherapy +/- radiotherapy (C +/- RT) for early-stage gastric cancer (ESGC). Compliance with these guidelines and the specific impact of adjuvant C +/- RT on overall survival (OS) in ESGC have not been extensively explored.
The National Cancer Data Base was queried for stage IB-II gastric adenocarcinoma patients undergoing gastrectomy (1998-2011). Multivariable modeling identified factors associated with adjuvant C +/- RT receipt and compared risk-adjusted OS by treatment type (i.e., adjuvant therapy versus surgery alone).
Of 23,461 ESGC patients (1998-2011), 79.4 % and 20.6 % received surgery alone and adjuvant C +/- RT (chemoradiotherapy 17.7 %; chemotherapy alone 2.9 %), respectively. Predictors of adjuvant C +/- RT receipt included age < 67 years, pathologic nodal positivity, and adequate lymph node staging (LNS; aeyen15 nodes examined; all p < 0.001). Survival analyses included 15,748 patients (1998-2006); median, 1-, and 5-year survival were 63.5 months, 86.0 %, and 27.0 % respectively. Omission of adjuvant C +/- RT conferred an increased hazard of risk-adjusted mortality in the overall cohort, and stage IB and II subgroups (all p aecurrency sign 0.001). The benefit of adjuvant C +/- RT was most pronounced in stage II and node-positive patients-regardless of LNS adequacy (all p < 0.001)-and inadequately staged IB patients (p = 0.003). While associated with a trend toward improved OS in node-negative patients overall (p = 0.051), adjuvant C +/- RT did not improve OS if surgical LNS was adequate in this subgroup (p = 0.960).
Adoption of adjuvant C +/- RT in ESGC remains incomplete nationally. Receipt of adjuvant therapy is associated with improved risk-adjusted survival relative to surgery alone; however, in adequately staged patients without lymph node metastasis, this benefit is less certain.

• 出版日期2016-9